<DOC>
	<DOCNO>NCT01410513</DOCNO>
	<brief_summary>Primary Objective : - To determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) SAR245409 administer combination rituximab bendamustine plus rituximab Secondary Objectives : - To determine safety tolerability SAR245409 combination rituximab bendamustine plus rituximab subject indolent Hon-Hodgkin Lymphoma ( iNHL ) Mantle Cell Lymphoma ( MCL ) Chronic Lymphocytic Leukemia ( CLL ) - To determine pharmacokinetics ( PK ) SAR245409 , bendamustine rituximab use combination subject iNHL , MCL CLL - To determine pharmacodynamic ( PD ) effect SAR245409 combination rituximab bendamustine plus rituximab subject iNHL , MCL CLL - To determine antitumor activity SAR245409 combination rituximab bendamustine plus rituximab subject iNHL , MCL CLL</brief_summary>
	<brief_title>Study Combining SAR245409 With Rituximab Bendamustine Plus Rituximab Patients With Indolent Lymphoma , Mantle Cell Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>All subject take SAR245409 twice daily . All subject receive SAR245409 long clinical benefit . Combination therapy SAR245409 , bendamustine rituximab , administer 28 day cycle 6 8 cycle . Subjects receive doublet combination , SAR245409 plus rituximab receive weekly rituximab 4 - 8 week . Monthly Rituximab may continue beyond 8 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : A confirmed diagnosis indolent nonHodgkin lymphoma , mantle cell lymphoma chronic lymphocytic leukemia Evaluable disease measurable disease Transfusion independent Able take oral medication Male Female subject &gt; 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Women childbearing potential use adequate contraception Exclusion criterion : Prior therapy PI3K , mTOR dual PI3K/mTOR inhibitor result adverse event necessitate treatment discontinuation Eligible hematopoietic stem cell transplant ( HSCT ) The subject receive investigational noninvestigational cytotoxic chemotherapy ( i.e. , cyclophosphamide ) , small molecule cancer therapy ( i.e. , imatinib ) , biologic cancer therapy rituximab ( i.e. , alemtuzumab , cytokine , vaccine monoclonal antibody ) hormonal therapy , radio immuno conjugate ( e.g . ibritumomab tiuxetan , tositumomab ) immunosuppressants treat malignancy within 4 week prior Cycle 1 , Day 1 Radiation therapy within 2 week prior Cycle 1 , Day 1 Autologous Hematopoietic Stem Cell Transplant ( HSCT ) within past 16 week Prior allogeneic HSCT Active central nervous system ( CNS ) metastases leptomeningeal involvement Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C Antibody ( antiHCV ) Hereditary acquire immunodeficiency syndrome human immunodeficiency virus ( HIV ) infection Active peptic ulcer disease require treatment proton pump inhibitor ( e.g . pantoprazole ) Type 2 histamine antagonist ( e.g . cimetidine ) Diagnosis treatment another malignancy within 3 year enrollment exception complete resection basal cell squamous cell carcinoma skin , situ malignancy lowrisk prostate cancer curative therapy Inadequate bone marrow function Abnormal liver function Abnormal renal function Abnormal coagulation The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>